Androgen receptor is a tumor suppressor and proliferator in prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 34, 2008, Pages 12182-12187

  Niu, Yuanjie ^a,b   Altuwaijri, Saleh ^a,c   Lai, Kuo Pao ^a   Wu, Chun Te ^a,d   Ricke, William A ^a   Messing, Edward M ^a   Yao, Jorge ^a   Yeh, Shuyuan ^a   Chang, Chawnshang ^a  

^a Departments of Pathology Urology and Radiation Oncology   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SAAD SPECIALIST HOSPITAL   (Saudi Arabia)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Androgen deprivation therapy; Metastasis; Testosterone; TGF 1

Indexed keywords

ANDROGEN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE LESION; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INFILTRATION; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CELL ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOCKOUT GENE; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR INTRINSIC ACTIVITY; WILD TYPE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; MALE; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 50449088732     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804700105     Document Type: Article

References (28)

1. Chang CS, Kokontis J, Liao ST (1988) Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324-326.
2. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
3. Miyamoto H, Messing EM, Chang C (2005) Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat Clin Pract Oncol 2:236-237.
4. Fluchter SH, Weiser R, Gamper C (2007) The role of hormonal treatment in prostate cancer. Recent Results Cancer Res 175:211-237.
5. Mizokami A, Yeh SY, Chang C (1994) Identification of 3′,5′- cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol 8:77-88.
6. Yuan S, et al. (1993) Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 53:1304-1311.
7. Webber MM, et al. (1999) A human prostatic stromal myofibroblast cell line WPMY-1: A model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20:1185-1192.
8. Heitzer MD, DeFranco DB (2006) Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 66:7326-7333.
9. Nagabhushan M, et al. (1996) CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56:3042-3046.
10. Yeh S, et al. (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 198:1899-1908.
11. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM (2002) Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 20:169-173.
12. Corey E, et al. (2002) Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52:20-33.
13. Gingrich JR, et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096-4102.
14. Wu X, et al. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61-69.
15. Wu CT, et al. (2007) Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 04:12679-12684.
16. Chen M, et al. (2007) Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis 45:44-50.
17. Litvinov IV, De Marzo AM, Isaacs JT (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88:2972-2982.
18. Van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA (2001) Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 195:563-570.
19. Gary B, et al. (2004) Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am J Path 164:1607-1614.
20. Grasl-Kraupp B, et al. (2003) Inherent increase of apoptosis in liver tumors: Implications for carcinogenesis and tumor regression. Hepatology 25:906-912.
21. Vakkala M, Lähteenmäki MK, Raunio H, Pääkkö P, Soini Y (1999) Apoptosis during breast carcinoma progression. Clin Cancer Res 5:319-324.
22. Patrawala L, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696-1708.
23. Pilatus U, et al. (2000) Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: The metabolic Boyden chamber. Neoplasia 2:273-279.
24. Kleeberger W, et al. (2007) Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 67:9199-9206.
25. Li R, et al. (2004) High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 28:928-934.
26. Easton DF, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:087-1093.
27. Niu Y, et al. (2008) Targeting the stromal androgen receptor in primary prostate tumors at earlier state. Proc Natl Acad Sci USA 105:12188-12193.
28. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C (2005) Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol Carcinog 44:1-10.